Nasdaq
$10.14▲ 1.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $890.6MShares out 87.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.14After-hours26.10.15 06:218-KKey event#●●●#●●●
Verastem, Inc.
Verastem, Inc. expects to raise approximately $234.7 million in net proceeds through an offering of 30,937,500 shares of common stock and pre-funded warrants to purchase up to 312,503 shares. The common stock is priced at $8.00 per share, with the offering expected to close on or about October 15, 2026.…more
$10.14+1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 06:18424B5Offering
Verastem, Inc.
Verastem is raising approximately $250 million through the offering of 30,937,500 shares of common stock and pre-funded warrants to purchase up to 312,503 shares. The offering price is set at $8.00 per share, with proceeds intended to support clinical development and general corporate purposes. This capital raise aims to accelerate the clinical trials and commercialization of the company's pipeline candidate, VS-7375.…more
$10.14+1.05%vs prev closeView filingShare - 10.14After-hours26.10.15 06:14424B5Offering
Verastem, Inc.
Verastem is conducting an offering of common stock and pre-funded warrants. The company reported positive interim data from its ongoing Phase 1/2 trial of the KRAS G12D inhibitor 'VS-7375' and plans to initiate a Phase 3 trial in the first-line setting by the end of 2026.…more
$10.14+1.05%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Regular26.10.14 23:17Bullish#●●●#●●●#●●●
Verastem Reports Positive Clinical Data for VS-7375 and Announces $250M Offering…more
Verastem Oncology reported promising clinical results for its KRAS inhibitor VS-7375 across multiple cancers and reached an agreement with the FDA on Phase 3 trial designs. Simultaneously, the company announced a $250 million equity offering to fund its clinical development programs.…more
$10.14+1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 19:05
●●●●●●●● ●●●●● ●●●●●●
Verastem Oncology announced robust clinical activity and a favorable safety profile for its VS-7375 candidate across multiple tumor types. Based on these results, the company plans to initiate a Phase 3 trial for first-line pancreatic cancer by the end of the year.…more
$10.14+1.05%vs prev closeShareBenzinga - 10.2Pre-market26.10.02 20:32
●●●●●●●● ●●●●● ●●●●●●
Verastem Oncology announced new molecular profiling and biomarker analysis from its Phase 2 RAMP 201 clinical trial for recurrent low-grade serous ovarian cancer. The data demonstrated statistically significant improvements in progression-free survival compared to conventional care.…more
$10.14+1.05%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report